Side-by-side · Research reference

TesofensinevsThymosin α-1

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 3Draft10/40 cited

BPhase 3Reviewed8/39 cited

Tesofensine

SNDRI · Phase 3 obesity candidate

0.25–0.5 mgDaily doseAstrup 2008

9.2 kgWeight ↓ (24 wk)Astrup 2008

Phase 3Evidence levelAstrup 2008

Oral · Once daily morning

Thymosin α-1

Immune modulator · Approved (some countries)

1.6 mgPer doseIyer 2007

Phase 3Evidence levelIyer 2007 Camerini 2001

~2 hrHalf-life

SQ · 2× weekly · 6+ months for chronic indications

01Mechanism of Action

Parameter

Tesofensine

Thymosin α-1

Primary target

Serotonin / norepinephrine / dopamine transporters (SERT / NET / DAT)Astrup 2008

Toll-like receptor 9 (TLR9) + T-cell maturation pathwayCamerini 2001

Pathway

Triple monoamine reuptake inhibition → ↑synaptic 5-HT, NE, DA → appetite suppression + thermogenesisAstrup 2008

TLR9 activation → ↑ IFN-α + IL-2 + IFN-γ → enhanced T-cell function + dendritic cell maturationIyer 2007

Downstream effect

Strong appetite suppression, mild thermogenic effect, weight lossAstrup 2008

Restored T-cell function, improved viral clearance, anti-tumour adjuvant effectsIyer 2007

Feedback intact?

—

Origin

Small molecule developed by NeuroSearch (Denmark) for CNS indications, repurposed for obesityAstrup 2008

Synthetic 28-AA peptide identical to natural Tα-1 isolated from thymus extractCamerini 2001

Antibody development

—

02Dosage Protocols

Parameter

Tesofensine

Thymosin α-1

Standard dose

0.25–0.5 mg / dayAstrup 2008

—

Frequency

Once daily, morning

2× weekly (Mon/Thu typical)

Lower / starter dose

0.125 mg / day

0.8 mg per injection

Evidence basis

Phase 2b + ongoing Phase 3Astrup 2008

Phase 3 + approved (35+ countries as Zadaxin)Iyer 2007

Duration

24 weeks per studied cycle

6–12 months for chronic indications

Form

Oral capsule

—

Timing

Morning to avoid sleep disruption

No specific time

Half-life

~9 days (very long)

~2 hours plasma; tissue effect days

Standard dose (HBV/HCV)

—

1.6 mg SQ 2× weekly × 6–12 monthsIyer 2007

Reconstitution

—

Sterile water for injection per vial label

04Side Effects & Safety

Parameter

Tesofensine

Thymosin α-1

Heart rate / BP

Dose-dependent ↑ HR + BPAstrup 2008

—

Insomnia

Dose-related; mitigate with morning timing

—

Dry mouth

Common

—

Nausea

Common

—

Mood changes

Anxiety / agitation possible

—

Cardiovascular events

Phase 3 trial monitoring; not yet FDA-cleared

—

Pregnancy / OB

Contraindicated

Avoid

Injection site reaction

—

Erythema, mild discomfort

GI symptoms

—

Rare nausea

Fatigue

—

Common during initial weeks

Fever / flu-like

—

Mild interferon-like response possible

Autoimmune

—

Theoretical risk; caution in active autoimmune disease

Cancer risk

—

No signal — used as adjuvant in oncology

Absolute Contraindications

Tesofensine

·Pregnancy / breastfeeding
·Severe cardiovascular disease
·Concurrent MAOI use

Thymosin α-1

·Pregnancy / breastfeeding
·Hypersensitivity to peptide
·Concurrent immunosuppressant therapy (transplant patients)

Relative Contraindications

Tesofensine

·Hypertension
·Anxiety disorder
·Insomnia

Thymosin α-1

·Active autoimmune disease
·Severe immunocompromised state without supervision

05Administration Protocol

Parameter

Tesofensine

Thymosin α-1

1. Form

Oral capsule (investigational; not commercial).

Add 1 mL sterile water per 1.6 mg vial → 1.6 mg/mL.

2. Administration

Swallow whole with water, morning only.

SQ — abdomen, thigh, or upper arm. Rotate sites.

3. Timing

Morning to mitigate insomnia. Do not dose evening.

2× weekly, e.g. Monday + Thursday.

4. Storage

Room temp ≤25 °C, dry place.

Lyophilised: refrigerate. Reconstituted: refrigerate, use within 24 h.

5. Caveat

Monitor BP + HR + mood. Avoid stimulants + MAOIs.

27–31G, 4–8 mm insulin syringe.